A study of vericiguat (MK-1242) in participants with chronic heart failure with reduced ejection fraction (HFrEF) (MK-1242-035) (VICTOR)
A study of vericiguat (MK-1242) in participants with chronic heart failure with reduced ejection fraction (HFrEF) (MK-1242-035) (VICTOR)
ClinicalTrials.gov ID: NCT05093933
Sponsor: Merck Sharp & Dohme LLC
Information provided by: Merck Sharp & Dohme LLC (Responsible Party)
Last Update Posted: 2024-11-18
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.
Official Title:
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction
Intervention / Treatment:
- Drug: Vericiguat
- Drug: Placebo
| Category | Value |
|---|---|
| Study Start (Actual) |
2021-11-02
|
| Primary Completion (Estimated) |
2025-03-31
|
| Study Completion (Estimated) |
2025-06-15
|
| Enrollment (Estimated) | 6000 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers | 1242-035 MK-1242-035 (Other Identifier) (OTHER: MSD) 2022-500881-80-00 (Registry Identifier) (REGISTRY: EU CT) 2020-005941-18 (EudraCT Number) |